Source · Select Committees · Science and Technology Committee (Commons)
Recommendation 1
1
Paragraph: 39
Robust clinical trial data lacking for long-term phage safety and immune interactions
Conclusion
The safety of phages has been well established mainly on the basis of observational evidence drawn from specific clinical interventions. However, as with all medicines, robust clinical trial data is important to provide and develop assurances around all aspects of patient safety, including the long-term impact of phages, especially their interaction with human immune systems, such as anaphylaxis and auto immune response.
Paragraph Reference:
39
Government Response
A response document is linked to this report, dated 1 March 2024. Response attribution to this conclusion has not been verified. Read the response document ↗